C. C. Taylor

发表

Dissolution Profile, Tolerability, and Acceptability of the Orally Disintegrating Olanzapine Tablet in Patients with Schizophrenia

P. Chue, B. Jones, R. Dickson, 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Dynorphin A 1–13 Stimulates Ovine Fetal Pituitary-Adrenal Function through a Novel Nonopioid Mechanism 1

H. Szeto, Y. Soong, J. Yee, 1997 .

Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent

G. Tollefson, C. C. Taylor, 2006 .

A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.

T. Hardy, M. Mitchell, E. Marquez, 2006, Clinical therapeutics.

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.

R. Palmer, A. Breier, M. Birkett, 2002, Archives of general psychiatry.

Olanzapine as Alternative Therapy for Patients With Haloperidol-Induced Extrapyramidal Symptoms: Results of a Multicenter, Collaborative Trial in Latin America

G. Mazzotti, M. Tohen, W. Gattaz, 2001, Journal of clinical psychopharmacology.

Morphine Stimulates Adrenocorticotropin and Cortisol Release in the Late-Term Ovine Fetus

H. Szeto, Dunli Wu, Y. Soong, 1997, Pediatric Research.

A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia

E. Dunayevich, G. Sethuraman, C. C. Taylor, 2005, Schizophrenia Research.

A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.

S. Lindborg, A. Breier, M. Birkett, 2003, Clinical therapeutics.

Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety during the First 24 Hours of Treatment

I. Bitter, S. Lindborg, B. Jones, 2003, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Cross-sectional Comparison of Fasting Lipids in Normoglycemic Patients With Schizophrenia During Chronic Treatment With Olanzapine, Risperidone, or Typical Antipsychotics

T. Hardy, E. Marquez, P. Cavazzoni, 2006, Journal of clinical psychopharmacology.

27. Rapid Onset of Absorption with Olanzapine Orally Disintegrating Tablets

J. Houston, H. Liu-Seifert, J. Witcher, 2004 .

An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

J. Lauriello, T. Lambert, D. McDonnell, 2008, The Journal of clinical psychiatry.

D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia

S. Kapur, M. Keshavan, M. Laruelle, 2008, Neuropsychopharmacology.

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

G. Tollefson, C. Beasley, V. Sutton, 2003, Journal of clinical psychopharmacology.

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

G. Tollefson, B. Kinon, B. Basson, 2001, The Journal of clinical psychiatry.

Is Quality of Life Among Minimally Symptomatic Patients With Schizophrenia Better Following Withdrawal or Continuation of Antipsychotic Treatment?

D. Naber, G. Sethuraman, C. Beasley, 2006, Journal of clinical psychopharmacology.

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.

A. Breier, B. Kinon, S. David, 2000, Clinical therapeutics.

Opioid modulation of the fetal hypothalamic-pituitary-adrenal axis: the role of receptor subtypes and route of administration.

H. Szeto, Dunli Wu, Y. Soong, 1997, The Journal of pharmacology and experimental therapeutics.

Characteristics of two alternative schizophrenia remission definitions: Relationship to clinical and quality of life outcomes

E. Dunayevich, G. Sethuraman, D. Lin, 2006, Schizophrenia Research.

All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics: An Integrated Analysis

E. Dunayevich, John M. Davis, C. Beasley, 2007, Journal of clinical psychopharmacology.

Response to Kujawa et al. letter-to-the-editor

E. Dunayevich, G. Sethuraman, C. C. Taylor, 2006, Schizophrenia Research.

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients

S. Lindborg, C. Beasley, K. Alaka, 2003, Psychiatry Research.